At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INKT MiNK Therapeutics, Inc.
Trading 12-22 14:11:59 EST
11.71
+0.12
+1.04%
High12.27Low11.70Vol7.25K
Open12.15D1 Closing11.59Amplitude4.92%
Mkt Cap54.97MTradable Cap19.94MTotal Shares4.69M
T/O87.04KT/O Rate0.43%Tradable Shares1.70M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors
Reuters  ·  11-21
MiNK Therapeutics Reports MiNK-215 Shows Strong Anti-Tumor Activity in Resistant Solid Tumors
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases
TIPRANKS  ·  11-15
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary Diseases
MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate
Benzinga  ·  11-14
MiNK Therapeutics Q3 EPS $(0.65) Misses $(0.61) Estimate
MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year
TIPRANKS  ·  11-14
MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year
Mink Therapeutics Q3 EPS USD -0.65
THOMSON REUTERS  ·  11-14
Mink Therapeutics Q3 EPS USD -0.65
Mink Therapeutics Inc: Cash Runway Extended Through 2026, Enabling Multiple Inflection Points
THOMSON REUTERS  ·  11-14
Mink Therapeutics Inc: Cash Runway Extended Through 2026, Enabling Multiple Inflection Points
Mink Therapeutics Reports Q3 2025 Results and Accelerates Inkt Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
THOMSON REUTERS  ·  11-14
Mink Therapeutics Reports Q3 2025 Results and Accelerates Inkt Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
Press Release: MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
Dow Jones  ·  11-14
Press Release: MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
BRIEF-Mink Therapeutics Inc - Files For Mixed Shelf Offering Up To $150 Million - SEC Filing
Reuters  ·  11-08
BRIEF-Mink Therapeutics Inc - Files For Mixed Shelf Offering Up To $150 Million - SEC Filing
MiNK Therapeutics files $150M mixed securities shelf
TIPRANKS  ·  11-08
MiNK Therapeutics files $150M mixed securities shelf
Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
TIPRANKS  ·  11-08
Promising Phase 1 Results for MiNK Therapeutics’ agenT-797 Support Buy Rating
BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive
Reuters  ·  11-08
BUZZ-U.S. STOCKS ON THE MOVE-Novo Nordisk, Block, Peloton Interactive
BUZZ-MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers
Reuters  ·  11-07
BUZZ-MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers
MiNK Therapeutics reports updated clinical results on agenT-797
TIPRANKS  ·  11-07
MiNK Therapeutics reports updated clinical results on agenT-797
MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors
Reuters  ·  11-07
MiNK Therapeutics Reports Durable Responses with Allo-iNKT Cell Therapy agenT-797 in Refractory Solid Tumors
Mink Therapeutics Reports Durable Responses and Immune Reactivation With Allo-Inkt Cell Therapy Agent-797 in Pd-1–Refractory Solid Tumors at SITC 2025
THOMSON REUTERS  ·  11-07
Mink Therapeutics Reports Durable Responses and Immune Reactivation With Allo-Inkt Cell Therapy Agent-797 in Pd-1–Refractory Solid Tumors at SITC 2025
Mink Therapeutics Inc - Agent-797 Well Tolerated Across All Treated Patients
THOMSON REUTERS  ·  11-07
Mink Therapeutics Inc - Agent-797 Well Tolerated Across All Treated Patients
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
GlobeNewswire  ·  11-05
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
MiNK Therapeutics Reports Durable Clinical Activity for AgenT-797 in Advanced Solid Tumors
Reuters  ·  10-30
MiNK Therapeutics Reports Durable Clinical Activity for AgenT-797 in Advanced Solid Tumors
Agenus Secures 10 Million Loan from Zydus Backed by MiNK Therapeutics Shares
Reuters  ·  10-10
Agenus Secures 10 Million Loan from Zydus Backed by MiNK Therapeutics Shares

Introduction

Company Name.
MiNK Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Issue price:
--